Dual-antiplatelet therapy + Dual-antiplatelet therapy
Pre-clinicalUNKNOWN 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Myocardial Infarction
Conditions
Acute Myocardial Infarction, Percutaneous Coronary Intervention, Major Adverse Cardiovascular Events, Bleeding
Trial Timeline
Jan 1, 2004 → Feb 1, 2018
NCT ID
NCT02806102About Dual-antiplatelet therapy + Dual-antiplatelet therapy
Dual-antiplatelet therapy + Dual-antiplatelet therapy is a pre-clinical stage product being developed by AstraZeneca for Acute Myocardial Infarction. The current trial status is unknown. This product is registered under clinical trial identifier NCT02806102. Target conditions include Acute Myocardial Infarction, Percutaneous Coronary Intervention, Major Adverse Cardiovascular Events.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02806102 | Pre-clinical | UNKNOWN |
Competing Products
20 competing products in Acute Myocardial Infarction